Effects of non-digestible carbohydrates on the growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in ovariectomized athymic mice

Nutrition and Cancer

Volumn 63, Issue 1, 2011, Pages 55-64

  Kondegowda, Nagesha Guthalu ^a   Meaney, Mary Pat ^a   Baker, Chandra ^a   Ju, Young H ^a  

^a VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE; ESTROGEN; ESTROGEN RECEPTOR; FRUCTOSE OLIGOSACCHARIDE;

APOPTOSIS; ARTICLE; BREAST CANCER; CELL PROLIFERATION; CELL STRAIN MCF 7; MOUSE; NONHUMAN; OVARIECTOMY; TUMOR GROWTH;

ANIMALS; CARBOHYDRATES; CELL LINE, TUMOR; CHOLESTEROL; ESTRADIOL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, HORMONE-DEPENDENT; OVARIECTOMY; TRANSPLANTATION, HETEROLOGOUS;

MUS; ZEA MAYS;

EID: 78751550117     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635581.2010.516871     Document Type: Article

References (94)

1. American Cancer Society: Cancer Statistics. American Institute of Cancer Research, Washington, DC, 2008.
2. Harlan LC, Abrams J, Warren JL, Clegg L, Stevens J, et al.: Adjuvant therapy for breast cancer: practice patterns of community physicians. J Clin Oncol 20, 1809-1817, 2002.
3. Pool-Zobel B: Inulin-type fructans and reduction in colon cancer risk: review of experimental and human data. Br J Nutr 93, S73-S90, 2005.
4. AACC: The definition of dietary fiber. Cereal Foods World 46, 112-126, 2001.
5. USDA: Dietary Guidelines for Americans. Office of Disease Prevention and Health Promotion, U.S. Department of Health and Human Services, Washington, DC, 2005.
6. Crittenden RG and Playne MJ: Production, properties and applications of food-grade oligosaccharides. Trends Food Sci Tech 7, 353-361, 1996.
7. Rivero-Urgell M, Santamaria-Orleans A, et al.: Oligosaccharides: application in infant food. Early Hum Dev 65, S43-S52, 2001.
8. Solange I and Mussattoa MM: Non-digestible oligosaccharides: a review. Carbohydrate Polymers 68, 587-597, 2007.
9. Fat Replacers: Food Ingredients for Healthy Eating, accessed 2007, .ast;www.caloriecontrol.org
10. Fibersol-2 Soluble Dietary Fiber. B&D Nutritional Ingredients, Inc.
11. Natural Hi-Maize. Natural Starch Food Innovation.
12. Molis C, Flourie B, Ouarne F, Gailing MF, Lartigue S, et al.: Digestion, excretion, and energy value of fructooligosaccharides in healthy humans. Am J Clin Nutr 64, 324-328, 1996.
13. Maiorano AE, Piccoli RM, da Silva ES, and de Andrade Rodrigues MF: Microbial production of fructosyltransferases for synthesis of prebiotics. Biotechnol Lett 30, 1867-1877, 2008.
14. Wang X and Gibson G: Effects of the in vitro fermentation of oligofructose and inulin by bacteria growing in the human large intestine. J Appl Bacteriol 75, 373-380, 1993.
15. Gibson GG, Beatty EB, Wang X, and Cummings JH: Selective stimulation of Bifidobacteria in the human colon by oligofructose and inulin. Gastroenterology 108, 975-982, 1995.
16. Gibson GR and Roberfroid MB: Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 125, 1401-1412, 1995.
17. Reddy G, Shabani KM, and Benerjee MR: Inhibitory effect of yogurt on Ehrlich-ascites-tumor cell proliferation. J Nat Cancer Inst 50, 815-817, 1973.
18. Reddy B and Rivenson A: Inhibitory effect of bifidobacterium longum on colon, mammary and liver carcinogenesis induced by 2-amino-3-methylimido-[4,5,- f]-quinoline, a food mutagen. Cancer Res 53, 3914-3918, 1993.
19. Roberfroid MB: Health benefits of non-digestible oligosaccharides. In: Dietary Fiber in Health and Disease, D Kritchevsky and C Bonfield (eds.). New York: Plenum Press, 1997, pp. 211-219.
20. Gibson GR, Beatty ER, Wang X, and Cummings JH: Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin. Gastroenterology 108, 975-982, 1995.
21. Hiriyama M: Novel physiological functions of oligosaccharides. Pure Appl Chem 74, 1271-1279, 2004.
22. Marteau P: Prebiotics and probiotics for gastrointestinal health. Clin Nutr 20, 41-45, 2001.
23. Manning TS and Gibson GR: Prebiotics. Best Practice Res Clin Gastroenterol 18, 287-298, 2004.
24. Kaur N and Gupta A: Applications of inulin and oligofructose in health and nutrition. J Biosci 27, 703-714, 2002.
25. Teitelbaum JE and Walker WA: Nutritional impact of pre-and probiotics as protective gastrointestinal organisms. Ann Rev Nutr 22, 107-138, 2002.
26. Kelly-Quagliana KA, Nelson PD, and Buddington RK: Dietary oligofructose and inulin modulate immune functions in mice. Nutr Res 23, 257-267, 2003.
27. Jenkins DJA, Kendall CWC, and Vuksan V: Inulin, oligofructose, and intestinal function. J Nutr 129, 1431S-1433S, 1999.
28. DelzenneNMandWilliams CM: Prebiotics and lipid metabolism. CurOpin Lipidol 13, 61-67, 2002.
29. Letexier D, Diraison F, andBeyoltM:Addition of inulin to amoderate highcarbohydrate diet reduces hepatic lipogenesis and plasma triacylglycerol concentrations in humans. Am J Clin Nutr 77, 559-564, 2003.
30. Pedersen A, Sandstrom B, and van Amelsvoort JMM:The effect of ingestion of inulin on blood lipids and gastrointestinal symptoms in healthy females. Br J Nutr 78, 215-222, 1997.
31. Sako T, Matsumoto K, and Tanaka R: Recent progress on research and applications of non-digestible galacto-oligosaccharides. Int Dairy J 9, 69-80, 1999.
32. van Dokkum W,Wezendonk B, Srikumar TS, and Van Den Heuvel EGHM: Effect of nondigestible oligosaccharides on large-bowel functions, blood lipid concentrations and glucose absorption in young healthymale subjects. Eur J Clin Nutr 53, 1-7, 1999.
33. Topping DL: Short-chain fatty acids produced by intestinal bacteria. Asia Pacific J Clin Nutr 5, 15-19, 1996.
34. Marteau P and Boutron-RaultMC: Nutritional advantages of probiotics and prebiotics. Br J Nutr 87, S153-S157, 2002.
35. Bornet FRJ and Brouns F: Immune-stimulating and gut health-promoting properties of short-chain fructo-oligosaccharides. Nutr Rev 60, 326-334, 2002.
36. Nangia-Makker PHV, Honjo Y, Baccarini S, Tait L, Bresalier R, et al.: Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst 94, 1854-1862, 2002.
37. Taper HS and Roberfroid MB: Influence of inulin and oligofructose on breast cancer and tumor growth. J Nutr 129, 1488S-1491S, 1999.
38. Taper HS and Roberfroid MB: Possible adjuvant cancer therapy by two prebiotics-inulin or oligofructose. In Vivo 19, 201-204, 2005.
39. Taper HS and Roberfroid MB: Inhibitory effect of dietary inulin or oligofructose on the development of cancer metastases. Anticancer Res 20, 4291-4294, 2000.
40. Cade JE, Burley VJ, and Greenwood DC: Dietary fibre and risk of breast cancer in the UK Women's Cohort Study. Int J Epidemiol 36, 431-438, 2007.
41. Soule HD, Vazguez J, Long A, Albert S, and BrennanM: A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 51, 1409-1416, 1973.
42. Ju YH, Allred KF, Allred CD, and Helferich WG: Genistein stimulates growth of human breast cancer cells in a novel, postmenopausal animal model, with low plasma estradiol concentrations. Carcinogenesis 27, 1292-1299, 2006.
43. McManus MJ and Welsch CW: Hormone-induced ductal DNA synthesis of human breast tissues maintained in the athymic nude mouse. Cancer Res 41, 3300-3305, 1981.
44. Ju YH, Clausen LM, Allred KF, Almada AL, and Helferich WG: Beta-Sitosterol, beta-sitosterol glucoside, and a mixture of beta-sitosterol and beta-sitosterol glucosidemodulate the growth of estrogen-responsive breast cancer cells in vitro and in ovariectomized athymic mice. J Nutr 134, 1145-1151, 2004.
45. Lonning PE, Geisler J, Johannessen DC, and Ekse D: Plasma estrogen suppression with aromatase inhibitors evaluated by a novel, sensitive assay for estrone sulphate. J Steroid Biochem Mol Biol 61, 255-260, 1997.
46. Reeves PG: Components of the AIN-93 diets as improvements in the AIN-76A diet. J Nutr 127, 838S-841S, 1997.
47. Gottardis MM,Wagner RJ, Borden EC, and Jordan VC: Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro. Cancer Res 49, 4765-4769, 1989.
48. Ju YH, Doerge DR, Allred KF, Allred CD, and Helferich WG: Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogendependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Res 62, 2474-2477, 2002.
49. Gibson GR and McCartney AL: Modification of the gut flora by dietary means. Biochem Soc T 26, 222-228, 1998.
50. Gibson GR and Roberfroid MB: Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 125, 1401-1412, 1995.
51. Gibson GR: Dietary modulation of the human gut microflora using the prebiotics oligofructose and inulin. J Nutr 129, 1438S-1441S, 1999.
52. Duggan C, Gannon J, and Walker WA: Protective nutrients and functional foods for the gastrointestinal tract. Am J Clin Nutr 75, 789-808, 2002.
53. Kaur N, Gupta A: Applications of inulin and oligofructose in health and nutrition. J Biosci 27, 703-714, 2002.
54. Sako T, Matsumoto K, and Tanaka R: Recent progress on research and applications of non-digestible galacto-oligosaccharides. Int Dairy J 9, 69-80, 1999.
55. van Dokkum W,Wezendonk B, Srikumar TS, and Van Den Heuvel EGHM: Effect of nondigestible oligosaccharides on large-bowel functions, blood lipid concentrations, and glucose absorption in young healthymale subjects. Eur J Clin Nutr 53, 1-7, 1999.
56. Taper HS, Delzenne NM, and Roberfroid MB: Growth inhibition of transplantable mouse tumors by non-digestible carbohydrates. Int J Cancer 71, 1109-1112, 1997.
57. Taper HS, Roberfroid MB: Possible adjuvant cancer therapy by two prebiotics-inulin or oligofructose. In Vivo (Athens, Greece) 19, 201-204, 2005.
58. Alison M: Assessing cellular proliferation: what's worth measuring? Hum Exp Toxicol 14, 935-944, 1995.
59. Yamashita K, Kawai K, and Itakura M: Effects of fructo-oligosaccharides on blood glucose and serum lipids in diabetic subjects. Nutr Res 4, 961-966, 1984.
60. Kok N, Roberfroid M, and Delzenne N: Involvement of lipogenesis in the lower VLDL secretion induced by oligofructose in rats. Br J Nutr 76, 881-890, 1996.
61. Higgins JA: Resistant starch:metabolic effects and potential health benefits. J AOAC Int 87, 761-768, 2004.
62. de Deckere EA, Kloots WJ, and van Amelsvoort JM: Resistant starch decreases serum total cholesterol and triacylglycerol concentrations in rats. J Nutr 123, 2142-2151, 1993.
63. de Deckere EA, Kloots WJ, and van Amelsvoort JM: Both raw and retrograded starch decrease serum triacylglycerol concentration and fat accretion in the rat. Br J Nutr 73, 287-298, 1995.
64. Cheng HH and Lai MH: Fermentation of resistant rice starch produces propionate reducing serum and hepatic cholesterol in rats. J Nutr 130, 1991-1995, 2000.
65. Lopez HW, Levrat-Verny MA, Coudray C, Besson C, Krespine V, et al.: Class 2 resistant starches lower plasma and liver lipids and improve mineral retention in rats. J Nutr 131, 1283-1289, 2001.
66. Kok K, Roberfroid M, and Delzenne N: Dietary oligofructose modifies the impact of fructose on hepatic triacylglycerol metabolism. Metabolism 45, 1547-1550, 1996a.
67. Delzenne N, Kok N, Fiordaliso M, Deboyser D, Goethals F, et al.: Dietary fructooligosaccharides modify lipid metabolism in rats. Am J Clin Nutr 57, 820s, 1993.
68. Aghelli N, Kabir M, Berni-Canani S, Petijean E, Boussairi A, et al.: Plasma lipids and fatty acid synthase activity are regulated by short-chain fructo-oligisaccharides in sucrose-fed insulin-resistant rats. J Nutr 128, 1283-1288, 1998.
69. Daubioul C, Taper H,Wislelaere L, and Delzenne N: Dietary oligofructose lessens hepatic steatosis, but does not prevent hyperglyceridemia in obese Zucker fa/fa rats. J Nutr 130, 1314-1319, 2000.
70. Flickinger E, Van Loo J, and Fahey G: Nutritional responses to the presence of inulin and oligofructose in the diets of domesticated animals. Crit Rev Food Sci Nutr 43, 19-60, 2003.
71. Yue W, Santen RJ, Wang JP, Hamilton CJ, and Demers LM: Aromatase within the breast. Endocr Relat Cancer 6, 157-164, 1999.
72. Anthony MC, Brown JMJ, Roberts M, and Chambon P: Activation of pS2 gene transcription is a primary response to estrogen in the human breast cancer cell line MCF-7. PNAS 81, 6344-6348, 1984.
73. Berry M and Chambon P: Estrogen-responsive element of the human pS2 gene is an imperfectly palindromic sequence. Proc Natl Acad Sci USA 86, 1218-1222, 1989.
74. Perillo B, Abbondanza C, and Palumbo G. 17-estradiol inhibits apoptosis in MCF-7 cells, including bcl-2 expression via two estrogen-responsive elements present in the coding sequence. Mol Cell Biol 20, 2890-2901, 2000.
75. Watts CK and Sarcevic B: Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Mol Endocrinol 9, 1804-1813, 1995.
76. Sherr CJ: Cancer cell cycles. Science 274, 1672-1677, 1996.
77. Watts CK andWarlters A: Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cancer cells. Breast Cancer Res Treat 31, 95-105, 1994.
78. Knudsen ES and Wang JY: Dual mechanisms for the inhibition of E2F binding to RB by cyclin-dependent kinase-mediated RB phosphorylation. Mol Cell Biol 17, 5771-5783, 1997.
79. Kato J, Matsushime H, Hiebert SW, Ewen ME, and Sherr CJ: Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev 7, 331-342, 1993.
80. Schafer KA: The cell cycle: a review. Vet Pathol 35, 461-478, 1998.
81. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 81, 323-330, 1995.
82. Prall OW and Musgrove EA: c-Myc or cyclin D1 mimics estrogen effects on cyclin E-cdk2 activation and cell cycle reentry. Mol Cell Bio 18, 4499-4508, 1998.
83. Foster JS andWimalasena J: Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells. Mol Endocrinol 10, 488-498, 1996.
84. Altucci L, Addeo, R, Cicatiello L, Dauvois S, Parker MG, et al.: 17beta-estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene 12, 2315-2324, 1996.
85. Musgrove EA, Lee, CS, Buckley MF, and Sutherland RL: Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc Natl Acad Sci USA 91, 8022-8026, 1994.
86. Zukerberg LR, Yang WI, Gadd M, Thor AD, Koerner FC, et al.: Cyclin D1 (PRAD1) protein expression in breast cancer: approximately one third of infiltrating mammary carcinomas show overexpression of the cyclin D1 oncogene. Mod Pathol 8, 560-567, 1995.
87. Jares P, Rey MJ, Fernandez, PL, Campo E, Nadal A, et al.: Cyclin D1 and retinoblastoma gene expression in human breast carcinoma: correlationwith tumour proliferation and oestrogen receptor status. J Pathol 182, 160-166, 1997.
88. Michalides R, Hageman P, van Tinteren H, Houben L, Wientjens E, et al.: A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br J Cancer 73, 728-734, 1996.
89. Hui R, Cornish AL, McClelland RA, Robertson JF, Blamey RW, et al.: Cyclin D1 and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer. Clin Cancer Res 2, 923-928, 1996.
90. Säaemann MD, Bohmih GA, Osterreicher CH, Burstcher, H, Parolini, O, et al.: Anti-inflammatory effects of sodium butyrate on human monocytes: potent inhibition of IL-12 and upregulation of IL-10 production. FASEB J 14, 2380-2382, 2000.
91. Cavaglieri CR, Nishiyama A, Fernandes LC, Curi R, Miles EA, et al.: Differential effects of short-chain fatty acids on proliferation and production of pro-and anti-inflammatory cytokines by cultured lymphocytes. Life Sci 73, 1683-1690, 2003.
92. Kurita-Ochiai T, Amano, S, Fukushima K, andOchiai K: Cellular events involved in butyric acid-induced T cell apoptosis. J Immunol 171, 3576-3584, 2003.
93. Inan MS, Rasoulpour R, Yin L, Hubbard RK, and Rosenberg DW: The luminal short-chain fatty acid butyrate modulates NFkappaB activity in a human colonic epithelial cell line. Gastroenterology 118, 724-734, 2000.
94. Pratt VC, Tappenden KA, McBurney MI, and Field CJ: Short-chain fatty acid-supplemented total parenteral nutrition improves nonspecific immunity after intestinal resection in rats. J Parenter Enteral Nutr 20, 264-271, 1996.